Literature DB >> 22628427

CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth.

Christina Claus1, Carsten Riether, Christian Schürch, Matthias S Matter, Tamara Hilmenyuk, Adrian F Ochsenbein.   

Abstract

Signaling of the TNF receptor superfamily member CD27 activates costimulatory pathways to elicit T- and B-cell responses. CD27 signaling is regulated by the expression of its ligand CD70 on subsets of dendritic cells and lymphocytes. Here, we analyzed the role of the CD27-CD70 interaction in the immunologic control of solid tumors in Cd27-deficient mice. In tumor-bearing wild-type mice, the CD27-CD70 interaction increased the frequency of regulatory T cells (Tregs), reduced tumor-specific T-cell responses, increased angiogenesis, and promoted tumor growth. CD27 signaling reduced apoptosis of Tregs in vivo and induced CD4(+) effector T cells (Teffs) to produce interleukin-2, a key survival factor for Tregs. Consequently, the frequency of Tregs and growth of solid tumors were reduced in Cd27-deficient mice or in wild-type mice treated with monoclonal antibody to block CD27 signaling. Our findings, therefore, provide a novel mechanism by which the adaptive immune system enhances tumor growth and may offer an attractive strategy to treat solid tumors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22628427     DOI: 10.1158/0008-5472.CAN-11-2791

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  52 in total

Review 1.  Stimulating CD27 to quantitatively and qualitatively shape adaptive immunity to cancer.

Authors:  Timothy Nj Bullock
Journal:  Curr Opin Immunol       Date:  2017-03-17       Impact factor: 7.486

2.  TGF-β upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin's lymphoma.

Authors:  Z-Z Yang; D M Grote; B Xiu; S C Ziesmer; T L Price-Troska; L S Hodge; D M Yates; A J Novak; S M Ansell
Journal:  Leukemia       Date:  2014-02-26       Impact factor: 11.528

Review 3.  TNF-receptor superfamily agonists as molecular adjuvants for cancer vaccines.

Authors:  Timothy Nj Bullock
Journal:  Curr Opin Immunol       Date:  2017-07-24       Impact factor: 7.486

4.  Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.

Authors:  Nizar M Tannir; Andres Forero-Torres; Radhakrishnan Ramchandren; Sumanta K Pal; Stephen M Ansell; Jeffrey R Infante; Sven de Vos; Paul A Hamlin; Stella K Kim; Nancy C Whiting; Elaina M Gartner; Baiteng Zhao; John A Thompson
Journal:  Invest New Drugs       Date:  2014-08-22       Impact factor: 3.850

Review 5.  Co-stimulatory and co-inhibitory pathways in cancer immunotherapy.

Authors:  Rachel E O'Neill; Xuefang Cao
Journal:  Adv Cancer Res       Date:  2019-04-17       Impact factor: 6.242

6.  Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies.

Authors:  Stephen M Ansell; Ian Flinn; Matthew H Taylor; Branimir I Sikic; Joshua Brody; John Nemunaitis; Andrew Feldman; Thomas R Hawthorne; Tracey Rawls; Tibor Keler; Michael J Yellin
Journal:  Blood Adv       Date:  2020-05-12

7.  CD57 ratio as a convenient and useful immunological and prognostic parameter for stage IV carcinoma.

Authors:  Junji Akagi; Hideo Baba
Journal:  Oncol Lett       Date:  2018-04-10       Impact factor: 2.967

8.  CD70 Inversely Regulates Regulatory T Cells and Invariant NKT Cells and Modulates Type 1 Diabetes in NOD Mice.

Authors:  Cheng Ye; Benjamin E Low; Michael V Wiles; Todd M Brusko; David V Serreze; John P Driver
Journal:  J Immunol       Date:  2020-08-31       Impact factor: 5.422

Review 9.  The promise and challenges of immune agonist antibody development in cancer.

Authors:  Patrick A Mayes; Kenneth W Hance; Axel Hoos
Journal:  Nat Rev Drug Discov       Date:  2018-06-15       Impact factor: 84.694

10.  Unveiling a CD70-positive subset of cancer-associated fibroblasts marked by pro-migratory activity and thriving regulatory T cell accumulation.

Authors:  Julie Jacobs; Vanessa Deschoolmeester; Karen Zwaenepoel; Tal Flieswasser; Christophe Deben; Jolien Van den Bossche; Christophe Hermans; Christian Rolfo; Marc Peeters; Olivier De Wever; Filip Lardon; Vasiliki Siozopoulou; Evelien Smits; Patrick Pauwels
Journal:  Oncoimmunology       Date:  2018-03-19       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.